Answers are grounded in this paper and cite their sources.
OBJECTIVES: The objective of this study was to clarify the clinicopathological features and prognostic factors of pulmonary pleomorphic carcinoma (PPC) in a multicenter setting. PATIENTS AND METHODS: We conducted a retrospective study of PPC patients across four hospitals between 2000 and 2021. Among 4425 resected cases of non-small cell lung cancer (NSCLC), 84 cases (1.9%) were diagnosed as PPC. Clinical records and pathological specimens were reviewed. RESULTS: PPC patients had significantly poorer recurrence-free survival (RFS) and overall survival (OS) than those with other NSCLC subtypes (5-year RFS: 33.0% vs. 59.7%, P < 0.001; 5-year OS: 45.1% vs. 69.7%, P < 0.001). Multivariate analysis identified two independent adverse prognostic factors for RFS: sarcomatoid component ≥50% and tumor necrosis ≥30%. Based on these two factors, PPC patients were stratified into three prognostic risk groups: high-risk (both factors), intermediate-risk (one), and low-risk (neither). The high-risk group demonstrated significantly worse RFS and OS compared with the low-risk group. Furthermore, PD-L1 expression was significantly higher in the high-risk group (median PD-L1 expression: 20% in low-risk, 70% in intermediate-risk, 80% in high-risk; P = 0.026). CONCLUSION: This study identified sarcomatoid component ≥50% and necrosis ≥30% as significant adverse prognostic indicators for RFS in PPC. Stratification into three prognostic risk groups based on these two features may aid in risk assessment and treatment planning. Notably, the high-risk group showed markedly elevated PD-L1 expression, suggesting its potential as a predictor of response to immune checkpoint inhibitors. Further large-scale prospective studies are warranted to validate these findings and improve therapeutic strategies for PPC. SHORT ASBSTRACT: This study analyzed 84 cases of pulmonary pleomorphic carcinoma (PPC). Multivariate analysis identified a sarcomatoid component ≥50% and tumor necrosis ≥30% as independent adverse prognostic factors for recurrence-free survival (RFS). Based on these two factors, PPC patients were stratified into three prognostic risk groups. Notably, the high-risk group exhibited significantly higher PD-L1 expression than the low-risk group, suggesting its potential as a predictor of response to immune checkpoint inhibitors.
No takes yet. Share an insight, caveat, or question.
Toyoda et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: